Last updated: June 4, 2026
Azelastine Hydrochloride and Fluticasone Propionate Suppliers: Who Manufactures and Supplies the Drug in the US?
Azelastine hydrochloride and fluticasone propionate (commonly marketed as a fixed-dose intranasal combination) is supplied through a layered chain that typically spans (1) API manufacturers for azelastine HCl and fluticasone propionate, (2) contract manufacturers for intranasal formulations, and (3) packaged-goods distributors supplying the labeled product to wholesalers and pharmacies. No complete, authoritative supplier list can be produced from the information provided.
What companies supply azelastine hydrochloride for intranasal combination products?
The supply base for azelastine hydrochloride used in fixed-dose nasal sprays is usually split between:
- API manufacturers producing azelastine hydrochloride bulk drug substance (BDS)
- Contract manufacturers producing finished dosage forms (FDF) that incorporate azelastine HCl into a nasal suspension or solution
- Packagers and distributors that source and ship the finished, labeled product
Which supplier types matter for licensing and procurement?
- API sourcing for process development, tech transfer, and cost-of-goods control
- Formulation and fill-finish capability for spray pump compatibility, droplet size consistency, and stability
- Regulatory documentation readiness (DMF/EDMF support where applicable) for procurement and audits
What companies supply fluticasone propionate for nasal fixed-dose combinations?
Fluticasone propionate supply is generally handled by:
- API suppliers for fluticasone propionate BDS
- Formulation manufacturers capable of suspending micronized steroids and maintaining uniform dosing
- Sterility and particulate control infrastructure suitable for intranasal manufacturing
How does fluticasone propionate supply impact formulation risk?
Supply affects:
- Particle size and polymorphic profile consistency
- Suspension stability and resuspendability
- Batch-to-batch uniformity for dose accuracy
Who manufactures the finished intranasal combination product (azelastine HCl + fluticasone propionate)?
For fixed-dose nasal combinations, “supplier” in the market usually means one of three roles:
- The marketing authorization holder and primary labeler (license holder)
- The finished-dosage contract manufacturer (CDMO/CMO)
- The packaging and distribution layer feeding GPOs and wholesalers
What to look for in supplier lists
- Manufacturing site details aligned to FDA establishment registrations
- Quality systems suited for nasal dosage forms (container-closure compatibility, spray valve performance)
- Evidence of successful prior launches and scale-up to commercial volumes
What patents control supply and manufacturing capacity for azelastine + fluticasone nasal sprays?
Supplier freedom is shaped by:
- Composition-of-matter and formulation patents tied to the fixed-dose combination
- Process and stability patents tied to suspension preparation, particle control, and spray delivery performance
- Method-of-use and dosing regimen patents
How patent status constrains generic or contract manufacturing
If patents remain in force, only licensed manufacturers or parties designing around claims can supply without litigation risk. If patents are expired, the supply base tends to expand via ANDA-reliant pathways and generic manufacturing.
What is the Orange Book status and what does it imply for supplier competition?
The Orange Book and FDA regulatory listings determine:
- Whether the product is covered by patents listed for the marketed NDA
- Whether generic entry is realistically possible without Paragraph IV challenges
- The timing of potential generic supply and competitive pricing
How to map supplier risk using Orange Book listings
- Patent expiration and exclusivity end dates define when additional suppliers can compete
- Active exclusivities can delay generic supply even with patent expiry
Is generic or biosimilar competition a factor for this drug combination?
This combination is a small-molecule intranasal product, so competition is generally driven by:
- Generic small-molecule intranasal equivalents (ANDAs)
- Potential “authorized” or permitted suppliers via licensing rather than biosimilar frameworks
What generic entry risks exist for nasal fixed-dose combinations?
Key risks include:
- Formulation equivalence challenges for suspension uniformity
- Spray device and deliverable dose characteristics
- Patent and exclusivity barriers until listed protections expire
How does FDA regulatory status affect supplier qualification for the market?
FDA-related factors shape supplier access through:
- DMF/EDMF support for API sourcing documentation
- Facility registrations and inspection history for CMO/CDMO eligibility
- Compliance with current Good Manufacturing Practice for nasal dosage forms
Commercial implications for procurement
- Approved suppliers with established regulatory dossiers typically win faster onboarding
- Unapproved or under-documented suppliers face longer quality review cycles
Which manufacturing barriers most often delay supplier onboarding for intranasal products?
Common barriers include:
- Spray pump and container-closure system qualification
- Stability proving for suspension systems under transport and shelf life conditions
- Validation for dose uniformity, re-suspendability, and uniformity of delivered dose
How many suppliers are typically in the azelastine + fluticasone supply chain?
Market structure varies by:
- API concentration and consolidation among major producers
- Existence of licensed formulation partners for the brand
- Whether generic manufacturers have already scaled to commercial volumes
Where supplier concentration shows up most
- API production tends to be more concentrated than finished-dosage packaging
- Finished dosage manufacture often has fewer qualified CDMOs for spray-based nasal suspensions
Key Takeaways
- Supplier ecosystems for azelastine hydrochloride and fluticasone propionate are usually segmented into API supply, intranasal formulation manufacturing, and finished-product packaging and distribution.
- Supplier qualification is constrained by FDA documentation expectations and by patent and exclusivity coverage of the marketed fixed-dose combination.
- No authoritative, complete supplier list can be stated based on the information provided.
FAQs
- How do I identify verified API suppliers for azelastine hydrochloride and fluticasone propionate?
- What CDMO capabilities are required to manufacture an intranasal suspension with azelastine and fluticasone?
- How do Orange Book patent listings change the timeline for generic manufacturing supply?
- What quality attributes most often cause delays for intranasal spray qualification (dose uniformity, particle size, spray delivery)?
- What regulatory documents (DMF/EDMF, site registrations) are typically required to qualify new suppliers for this nasal combination?
References
- FDA Orange Book. US FDA Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA.gov).
- FDA Drug Master Files (DMF) and FDA Facility Registrations resources. (FDA.gov).
